Hypertension: Covidien launches OneShot renal denervation sales in global markets
Medical device maker launches commercial sales of its OneShot renal denervation system in Europe, Middle East, Africa, Asia and Latin America.
Medical device maker Covidien (NYSE:COV) this week announced commercial launch of its OneShot renal denervation system in markets around the world, bringing the company up to speed with some of its renal denervation rivals.
Over the next few months Covidien will roll out the device in markets in Europe, the Middle East, Africa, Asia and Latin America, according to a press release. No renal denervation system has yet been approved for sale in the U.S.